Tags

Type your tag names separated by a space and hit enter

A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children.
Am J Dis Child. 1991 Jul; 145(7):734-41.AJ

Abstract

The reactogenicity and immunogenicity of the Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids were compared in 139 infants aged 3 to 8 months, 60 infants and children aged 9 to 23 months, and 99 children aged 24 to 30 months. Good antibody responses to pertussis toxin (PT), filamentous hemagglutinin (FHA), and agglutinogens occurred in all age groups after both the third and fourth doses. After the fourth (booster) dose, the mean antibody values in initially seronegative infants vaccinated at 3 to 8 months of age were as follows: anti-PT, 67.8 enzyme-linked immunosorbent assay units (EU) per milliliter; anti-FHA, 149.5 EU/mL; the agglutinin titer was 125.6. The values in initially seronegative children vaccinated at 24 to 30 months of age were as follows: anti-PT, 92.9 EU/mL; anti-FHA, 251.7 EU/mL; the agglutinin titer was 275.8. Reactions following immunization were minimal. Except for drowsiness after the first dose in infants, there were no clinically significant differences in reactions between infants and older children. The findings in this study coupled with the recent demonstration of efficacy of this vaccine in 2-year-old children supports the recent Japanese recommendation to lower the age of immunization with acellular pertussis vaccine combined with tetanus and diphtheria toxoids to 3 months.

Authors+Show Affiliations

Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2058603

Citation

Kimura, M, et al. "A Comparative Trial of the Reactogenicity and Immunogenicity of Takeda Acellular Pertussis Vaccine Combined With Tetanus and Diphtheria Toxoids. Outcome in 3- to 8-month-old Infants, 9- to 23-month-old Infants and Children, and 24- to 30-month-old Children." American Journal of Diseases of Children (1960), vol. 145, no. 7, 1991, pp. 734-41.
Kimura M, Kuno-Sakai H, Sato Y, et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. Am J Dis Child. 1991;145(7):734-41.
Kimura, M., Kuno-Sakai, H., Sato, Y., Kamiya, H., Nii, R., Isomura, S., Horiuchi, K., Kato, T., Deguchi, M., & Saikusa, H. (1991). A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. American Journal of Diseases of Children (1960), 145(7), 734-41.
Kimura M, et al. A Comparative Trial of the Reactogenicity and Immunogenicity of Takeda Acellular Pertussis Vaccine Combined With Tetanus and Diphtheria Toxoids. Outcome in 3- to 8-month-old Infants, 9- to 23-month-old Infants and Children, and 24- to 30-month-old Children. Am J Dis Child. 1991;145(7):734-41. PubMed PMID: 2058603.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. A1 - Kimura,M, AU - Kuno-Sakai,H, AU - Sato,Y, AU - Kamiya,H, AU - Nii,R, AU - Isomura,S, AU - Horiuchi,K, AU - Kato,T, AU - Deguchi,M, AU - Saikusa,H, PY - 1991/7/1/pubmed PY - 1991/7/1/medline PY - 1991/7/1/entrez SP - 734 EP - 41 JF - American journal of diseases of children (1960) JO - Am J Dis Child VL - 145 IS - 7 N2 - The reactogenicity and immunogenicity of the Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids were compared in 139 infants aged 3 to 8 months, 60 infants and children aged 9 to 23 months, and 99 children aged 24 to 30 months. Good antibody responses to pertussis toxin (PT), filamentous hemagglutinin (FHA), and agglutinogens occurred in all age groups after both the third and fourth doses. After the fourth (booster) dose, the mean antibody values in initially seronegative infants vaccinated at 3 to 8 months of age were as follows: anti-PT, 67.8 enzyme-linked immunosorbent assay units (EU) per milliliter; anti-FHA, 149.5 EU/mL; the agglutinin titer was 125.6. The values in initially seronegative children vaccinated at 24 to 30 months of age were as follows: anti-PT, 92.9 EU/mL; anti-FHA, 251.7 EU/mL; the agglutinin titer was 275.8. Reactions following immunization were minimal. Except for drowsiness after the first dose in infants, there were no clinically significant differences in reactions between infants and older children. The findings in this study coupled with the recent demonstration of efficacy of this vaccine in 2-year-old children supports the recent Japanese recommendation to lower the age of immunization with acellular pertussis vaccine combined with tetanus and diphtheria toxoids to 3 months. SN - 0002-922X UR - https://www.unboundmedicine.com/medline/citation/2058603/A_comparative_trial_of_the_reactogenicity_and_immunogenicity_of_Takeda_acellular_pertussis_vaccine_combined_with_tetanus_and_diphtheria_toxoids__Outcome_in_3__to_8_month_old_infants_9__to_23_month_old_infants_and_children_and_24__to_30_month_old_children_ DB - PRIME DP - Unbound Medicine ER -